You are currently here:

You are here

Independent Grant Process

Pfizer is continuously striving to improve its process with the goal of ensuring regulatory compliance while providing independent grants to support initiatives that accelerate the translation of clinical science into quality patient care.



Track 1 – Healthcare Quality Improvement & Education

The strategic global priorities for Healthcare Quality Improvement & Education for the current year are:

  • Hemophilia
  • Inflammation
  • Pain
  • Vaccines

RFPs will be posted on our website. In addition, they will also be disseminated through e-mail to all registered organizations. IGLC expects to release 2-3 RFPs per clinical area per year. Please visit the Request for Proposals section of this site for details regarding open RFPs.

Track 2 – Knowledge Gap

Knowledge Gap grants will focus on educational strategies specially designed to close gaps in knowledge and improve competence in certain clinical areas, as identified through needs assessment and other data that would support this type of strategy. Types of funding currently available include:

  • Annual Meeting Support: Eligible organizations can request funding to support LIVE national and regional conferences and congresses. CLICK HERE to view the current year clinical areas of interest and goals as well as submission deadlines.
  • Call for Grant Applications (CGA): In certain clinical areas, a Call for Grant Applications (CGA) will also be posted. The CGA will describe (1) the clinical area of interest, (2) the approximate total budget available, (3) the rationale behind the need for knowledge-driven education or assessment, (4) the outcome-reporting required, and (5) what information must be in the application.  To view previously posted CGAs that are now closed (i.e., applications no longer accepted) please click here.
    • Currently open CGAs:
CGA ID # Geographic Scope Issue Date CGA Submission Deadline
CGA16RA5 United States August 10, 2016 The Role of Novel Therapies and Kinase Inhibition in the Management of RA October 14, 2016
CGA16IBD3 United States August 15, 2016 Gastroenterology Visiting Professorships October 14, 2016
CGA16ON5 United States August 16, 2016 Geriatric Oncology Needs Assessment October 12, 2016
CGA16ON6 United States August 16, 2016 Metastatic Breast Cancer Visiting Professorships November 16, 2016
CGA16AD1 United States August 25, 2016 Emerging Therapies in the Treatment of Atopic Dermatitis (Eczema) October 21, 2016
CGA16RC1 United States September 9, 2016 Addressing Knowledge Gaps in Implementing Risk Communication Recommendations October 21, 2016
CGA16VA4 United States September 23, 2016 Knowledge Gaps in Serogroup B Meningococcal (MenB) Disease October 26, 2016
CGA16HEM1 North America, Europe, Turkey, Israel, Kuwait, Saudi Arabia, UAE, Japan, South Korea, Malaysia, New Zealand, Australia, Argentina, Brazil, Colombia September 30, 2016 Gene Therapy in Hemophilia Visiting Professorship November 16, 2016
CGA16HEM2 North America, Europe, Saudi Arabia and Gulf countries, Jordan, Lebanon, Egypt, Algeria, Morocco, Taiwan, China, Costa Rica, Brazil, Colombia, Argentina September 30, 2016 Point of Care Ultrasound in Hemophilia Visiting Professorship November 16, 2016
CGA16DS1 Global October 3, 2016 Dietary Intakes, Safety, and Public Health Value of Calcium November 11, 2016
CGA16DS2 United States October 3, 2016 Role of Key Nutrients and Dietary Supplements for Healthy Skin Appearance November 11, 2016

 Clinical Areas Reviewed through Joint Alliances/Partnerships


Organizations Eligible to Receive Grants and Process Overview

Pfizer is committed to supporting healthcare quality improvement initiatives, continuing professional development and other independent education activities, including CME/CE, that are most likely to improve patient health, and believe that the likelihood of improving patient health increases when education is integrated with quality. We believe commercial support should be aligned with the literature on effective continuing education for health professionals, and the highest level of standards endorsed by the medical community such as those found in the 2006 ACCME criteria.

Types of organizations eligible to apply for grants include hospitals, academic medical centers, schools of nursing or pharmacy, professional societies and associations, and other entities with a mission related to healthcare professional education and/or healthcare improvement.View further details about eligibility.

View the full description of the grant application process.



Throughout the year Independent Grants for Learning & Change (IGLC) may send out communications directly to registered users of the Pfizer Grant Management System (GMS) with regard to important and time-sensitive topics (e.g., change in policy, changes in process or procedures, system enhancements). Such communications are posted below for your reference in descending chronological order. In addition to announcements prepared by IGLC, posted below you will find other relevant information we wish to share with our stakeholder community.


Date Posted Description Link
01/31/16 IGLC Sunshine FAQ - updated Jan 2016
02/28/15 IGLC Sunshine FAQ - updated Feb 2015
10/02/13 Press Release: International Atherosclerosis Society And Pfizer Independent Grants For Learning & Change Collaborate On New Grant Opportunity
08/30/13 Sunshine FAQ following IGLC webinar
08/01/13 Sunshine Act: Final Regulations and Implications for our Independent Grants Program
04/08/13 Pfizer IGLC announces new name
01/02/13 NEW online Grant Management System
09/13/12 Women's Health Platform
02/07/12 FAQ about new model
01/03/12 Pfizer MEG announces new model
12/27/11 Seeking nominations for External Review Panel Members
03/25/11 Pfizer Medical Education Group — King integration
11/04/09 Pfizer's support of ACCME Transparency Statement
10/20/09 Pfizer Medical Education Group – integration
12/03/08 Change in Pfizer's CME Grant Policy pursuant to state Attorneys General settlement-CME faculty with promotional speaking involvement
9/15/08 Pfizer's response to ACCME Call for Comments
7/18/08 Statement on Pfizer's recent policy change re CME support
7/18/08 FAQs re Pfizer's recent policy change re CME support
7/02/08 Pfizer announces policy change re CME support


File Description

Approved Full Proposal Final Report Overview

Upon completion of a project funded through a Request for Proposal (RFP), grant recipients will be asked to complete a "Full Proposal Final Report". This is a copy of the final report questions that will be asked.

Approved Full Proposal Interim Report Overview


Throughout the lifecycle of a project funded through a Request for Proposal (RFP), grant recipients will be asked to complete a "Full Proposal Interim Report". This is a copy of the interim report questions that will be asked.

Request for Scope Change

If a request for a timeline extension/scope change is received by Pfizer, a report will be assigned to the Grant Requestor in the Grant Management System. This is a copy of the questions that will be asked. 

Project Classification Decision Matrix

There are multiple project types that are eligible for funding through an IGLC RFP. When submitting for funding, organizations will be asked to indicate which of the following best represents their project.

  • Dissemination and Implementation (D&I) Research
  • Quality Improvement  Education
  • Educational research

This file provides more information on these classifications.


Your Application

Apply for a grant or view the status of your existing application.